← Leaderboards
Robert F. Spurney
Durham Va Medical Center
$6,612,209
Attributed
$6,612,209
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $722.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,612,209 · 6
VA$0 · 3
By mechanism
R01$5,321,877 · 4
T32$847,582 · 1
R21$442,750 · 1
I01$0 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Podocyte”
- Stuart Shankland · University Of Washington$22,724,098
- Martin R. Pollak · Beth Israel Deaconess Medical Center$18,601,131
- Sumant Singh Chugh · Rush University Medical Center$15,917,525
- Patricio Ernesto Ray · Children'S National Medical Center$13,899,539
- Erwin P. Bottinger · Yeshiva University$12,927,665
- John C He · James J Peters Va Medical Center$12,792,446
Research focus
PodocyteKidneyInjuryPlayCharacteristicsSignal TransductionRenal Glomerular DiseasePathogenesisIn VivoCellsKidney DiseasesUnited StatesProteinuriaApoptosisMediatingInsulin-Dependent Diabetes MellitusMouse ModelResearch StudyDiabetic NephropathyApplications GrantsReceptorSignal PathwayBasePromotor (Genetics)
Grant awards (35)
Promoting podocyte protective cGMP signaling in diabetic kidney disease$0
I01 · FY2025 · VA · contact PI
Promoting podocyte protective cGMP signaling in diabetic kidney disease$0
I01 · FY2024 · VA · contact PI
A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS)$201,250
R21 · FY2023 · TR · contact PI
Promoting podocyte protective cGMP signaling in diabetic kidney disease$0
I01 · FY2023 · VA · contact PI
A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS)$241,500
R21 · FY2022 · TR · contact PI
Duke Training Grant in Nephrology$228,035
T32 · FY2019 · DK · contact PI
Novel Targets for the Treatment of Diabetic Kidney Disease$0
I01 · FY2019 · VA · contact PI
Duke Training Grant in Nephrology$211,058
T32 · FY2018 · DK · contact PI
Novel Targets for the Treatment of Diabetic Kidney Disease$0
I01 · FY2018 · VA · contact PI
Duke Training Grant in Nephrology$194,364
T32 · FY2017 · DK · contact PI
Duke Training Grant in Nephrology$1,512
T32 · FY2017 · DK · contact PI
Novel Targets for the Treatment of Diabetic Kidney Disease$0
I01 · FY2017 · VA · contact PI
Duke Training Grant in Nephrology$212,613
T32 · FY2016 · DK · contact PI
Novel Targets for the Treatment of Diabetic Kidney Disease$0
I01 · FY2016 · VA · contact PI
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus$341,475
R01 · FY2014 · DK · contact PI
Mechanisms of proteinuria induced by RhoA GTPases$0
I01 · FY2014 · VA · contact PI
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus$329,524
R01 · FY2013 · DK · contact PI
Mechanisms of proteinuria induced by RhoA GTPases$0
I01 · FY2013 · VA · contact PI
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus$341,475
R01 · FY2012 · DK · contact PI
Mechanisms of proteinuria induced by RhoA GTPases$0
I01 · FY2012 · VA · contact PI
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus$386,515
R01 · FY2011 · DK · contact PI
A Novel Mouse Model of Podocyte Injury$335,907
R01 · FY2011 · DK · contact PI
Mechanisms of proteinuria induced by RhoA GTPases$0
I01 · FY2011 · VA · contact PI
A Novel Mouse Model of Podocyte Injury$336,960
R01 · FY2010 · DK · contact PI
A Novel Mouse Model of Podocyte Injury$134,204
R01 · FY2010 · DK · contact PI
A Novel Mouse Model of Podocyte Injury$364,454
R01 · FY2009 · DK · contact PI
Regulation of Podocyte Function By Angiotensin II$302,655
R01 · FY2008 · DK · contact PI
Regulation of Podocyte Function By Angiotensin II$308,832
R01 · FY2007 · DK · contact PI
Regulation of Podocyte Function By Angiotensin II$318,056
R01 · FY2006 · DK · contact PI
Regulation of Podocyte Function By Angiotensin II$325,710
R01 · FY2005 · DK
Regulation of Podocyte Function By Angiotensin II$325,710
R01 · FY2004 · DK
G-PROTEIN COUPLED RECEPTOR KINASES IN OSTEOGENESIS$292,600
R01 · FY2004 · AR
G-PROTEIN COUPLED RECEPTOR KINASES IN OSTEOGENESIS$292,600
R01 · FY2003 · AR
G-PROTEIN COUPLED RECEPTOR KINASES IN OSTEOGENESIS$292,600
R01 · FY2002 · AR
G-PROTEIN COUPLED RECEPTOR KINASES IN OSTEOGENESIS$292,600
R01 · FY2001 · AR